Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+) - Morgensztern, D; Govindan, R; Cobo, M; Ponce Aix, S; Postmus, PE; Lewanski, C; Bennouna, J; Fischer, J; Juan-Vidal, O; Stewart, D; Ardizzoni, A; Bhore, R; et al. (Elsevier, 2018)